Quercetin Protects Cataract Lenses by Modulating Hippo Signaling

Study Background and Research Question

Cataracts remain the leading cause of blindness worldwide, disproportionately impacting older populations and individuals in regions with limited access to surgery. While surgical removal of the opacified lens is highly effective, the global burden and practical barriers underscore an urgent need for pharmacological interventions that can delay or prevent cataract progression. Traditional Chinese medicine (TCM) and its bioactive natural products have emerged as promising candidates, with several herbal extracts exhibiting antioxidant and cytoprotective effects in the lens. However, the precise molecular mechanisms through which these agents confer lens protection are often unresolved.

Within this context, the Hippo signaling pathway has attracted attention as a regulator of cell proliferation, apoptosis, and tissue homeostasis in the lens. Dysregulation of Hippo components, such as MST1/2, YAP, and TAZ, has been linked to abnormal lens epithelial cell (LEC) behavior—central to cataractogenesis. The current study by Sheng Miao and Zhuxian Feng (Int Ophthalmol, 2025) investigates whether quercetin, a polyphenolic flavonoid with known antioxidant activity, mitigates cataract pathology through modulation of the Hippo pathway, and explores how Hippo activation or inhibition impacts lens protection and LEC proliferation.

Key Innovation from the Reference Study

The principal innovation in this research lies in its integrated, pathway-targeted approach: using network pharmacology to identify quercetin as a top candidate for Hippo pathway modulation, and then validating its effects in both in vivo and in vitro cataract models. By directly interrogating the interplay between quercetin and Hippo signaling, the study provides mechanistic clarity that bridges natural product pharmacology with cell signaling science. Notably, it establishes that suppression of Hippo signaling—rather than mere antioxidant action—plays a pivotal role in quercetin's protective effects on the lens.

Methods and Experimental Design Insights

The study design combines computational, in vivo, and in vitro strategies for comprehensive mechanistic evaluation:

• Network Pharmacology: The authors used a network-based approach to screen for cataract-related targets and signaling pathways, nominating quercetin as a top Hippo-associated compound due to its high overlap with key pathway nodes.
• In Vivo Cataract Model: A UVB-induced cataract mouse model was established. Mice received quercetin with or without the Hippo pathway activator α-hederin. Lens opacity, histopathology, and oxidative stress markers (malondialdehyde [MDA], glutathione [GSH], superoxide dismutase [SOD]) were quantified. Expression of Hippo pathway proteins and proliferation/apoptosis markers (p-MST1, p-YAP, TAZ, Ki-67, BCL-2, BAX, Cleaved Caspase-3) was measured by immunohistochemistry and western blotting.
• In Vitro Cell Model: Mouse lens epithelial cells were subjected to H₂O₂-induced oxidative injury and treated analogously with quercetin, ± α-hederin. Cell proliferation was assessed via CCK-8 assay, and pathway protein expression was analyzed.

This design enables robust testing of both the preventive and mechanistic hypotheses, establishing causal links between pathway modulation and phenotypic outcomes.

Core Findings and Why They Matter

Key findings from the reference study can be summarized as follows:

• Hippo Pathway as a Cataract Target: Network analysis identified the Hippo signaling cascade as the most significantly enriched pathway among cataract-associated targets, with quercetin demonstrating the strongest overlap.
• Quercetin Reduces Lens Opacity and Oxidative Stress: In UVB-cataract mice, quercetin treatment decreased lens opacity, preserved lens histo-architecture, reduced MDA, and increased GSH and SOD—signifying robust antioxidant effects and tissue protection.
• Suppression of Hippo Signaling: Quercetin lowered levels of phosphorylated MST1, YAP, and TAZ, indicating pathway inactivation. This was correlated with increased Ki-67 and BCL-2 (proliferation/survival markers), and decreased BAX and cleaved Caspase-3 (apoptosis markers), supporting enhanced epithelial cell survival.
• Role of Hippo Reactivation: Administration of α-hederin reversed the protective and biochemical effects of quercetin, restoring Hippo pathway activation and increasing lens damage and oxidative stress.
• In Vitro Confirmation: Similar effects were replicated in H₂O₂-injured lens epithelial cells, where quercetin promoted cell proliferation and suppressed Hippo signaling; these effects were again reversed by α-hederin.

Collectively, these results indicate that the protective action of quercetin in cataract models is at least partly attributable to suppression of the Hippo pathway, in addition to its antioxidant properties. This not only clarifies the molecular basis of a traditional medicine but also provides a roadmap for developing targeted, non-surgical cataract interventions that modulate cell fate via specific signaling cascades.

Comparison with Existing Internal Articles

Internal resources further contextualize these findings and reinforce their relevance in the field of pathway-targeted therapeutics. For example, a recent article (Quercetin Protects Cataract Lenses by Modulating Hippo Signaling) echoes the central observation that quercetin alleviates lens damage by suppressing Hippo activation and improving epithelial survival. Similarly, another review (Quercetin Modulates Hippo Pathway to Protect Cataract Lenses) underscores that Hippo pathway inactivation is mechanistically linked to improved oxidative stress responses in lens cells. These internal analyses align with the reference study in highlighting Hippo signaling as a promising pharmacological target in cataract prevention and in validating quercetin's dual antioxidant and pathway-modulatory effects.

By comparison, research on other targeted pathway inhibitors—such as selective ROCK inhibitors including Fasudil (HA-1077) HCl—has focused on manipulating cell proliferation, migration, and apoptosis in cancer and hematological models (Fasudil (HA-1077) HCl: Selective ROCK Inhibitor—Mechanisms & Evidence). While the molecular targets differ, both strategies exemplify the value of pathway-specific modulation in controlling cell fate and disease progression.

Limitations and Transferability

Despite its strengths, the study presents several limitations that affect the generalizability and translational potential of its findings. First, the in vivo experiments were conducted exclusively in a UVB-induced mouse cataract model, which may not recapitulate all human cataract etiologies. The study's reliance on α-hederin as a Hippo activator, while pharmacologically relevant, does not fully capture physiological regulatory complexity. Additionally, long-term safety, optimal dosing, and pharmacokinetics of quercetin in ocular tissues remain to be addressed in future work.

Transferability to the human clinical setting is further limited by interspecies differences in lens biology and oxidative stress responses. While in vitro data in mouse LECs support the mechanistic conclusions, human validation—in both lens tissue and clinical endpoints—is essential before translation into therapeutic development. Finally, the study does not directly compare quercetin to other established or experimental pathway inhibitors, such as selective ROCK inhibitors, in the context of lens protection or cataractogenesis.

Protocol Parameters

• Quercetin administration in cataract mouse model: Delivered in vivo following UVB-induced cataract formation; co-administered with α-hederin for pathway modulation.
• Oxidative stress induction in vitro: Mouse lens epithelial cells exposed to H₂O₂ to simulate cataract-associated injury prior to treatment.
• Pathway protein analysis: Both western blotting and immunohistochemistry used to quantify MST1, YAP, TAZ, and apoptotic/proliferative markers.
• Functional assessment: Lens opacity scoring, CCK-8 proliferation assay, and quantification of MDA, GSH, and SOD.

Research Support Resources

For researchers interested in dissecting cell signaling mechanisms underlying proliferation, migration, and apoptosis in disease models, selective pathway modulators are essential. For studies focused on the Rho/ROCK signaling axis, Fasudil (HA-1077) HCl (SKU A5734) from APExBIO is a widely used, potent ROCK inhibitor. According to the existing literature, Fasudil enables precise manipulation of cellular behaviors in cancer and hematological models by inhibiting ROCK-I and ROCK-II without affecting upstream RhoA activity. Its well-characterized solubility and storage parameters support diverse experimental workflows. While the Hippo pathway and Rho/ROCK pathway are distinct, both represent actionable nodes for regulating cell survival and tissue integrity, making Fasudil a valuable tool for comparative or combinatorial pathway studies in cell biology and disease modeling.